regenHU and Wako Automation Collaborate to Promote 3D Bioprinting in Drug-discovery in the USA
Leading bioprinter manufacturer regenHU appointed Wako Automation as their official systems integrator for the USA. Recent advances in 3D-Bioprinting provide a valuable tool in the fabrication of biomimetic tissue constructs which can be applied at various stages of drug discovery research and development.
“The collaboration with regenHU will enable customers at the forefront of drug discovery to fully integrate regenHU 3D Bioprinters into advanced drug discovery systems” Robert Bukar, Director of Business Development at Wako Automation.
regenHU — a three-dimensional biotechnology company exploiting the potential of 3D bioprinting & cell-based therapies — is leading the development of biomedical products for regenerative medicine & drug discovery by combining efforts with Wako Automation, a San Diego based lab automation solutions provider, to integrate 3D Bioprinting solutions into automated drug discovery systems.
“The synergies of our expertise offer a unique value solution to leading pharma & biotech innovators allowing us to individualize the specific needs of each development”. Marc Thurner, CEO of regenHU.
Wako Automation is an experienced lab automation solution provider and leading distributor of Yokogawa’s CV8000 confocal high content screening system known for its high speed and flexibility. “Microscopy and additive manufacturing” are two key components of our customers’ drug development process.
Wako Automation and regenHU will demonstrate their technology at the SLAS Conference in San Diego next February 3-7.
